vs
COFFEE HOLDING CO INC（JVA）与MEDIFAST INC（MED）财务数据对比。点击上方公司名可切换其他公司
MEDIFAST INC的季度营收约是COFFEE HOLDING CO INC的2.7倍（$75.1M vs $27.7M）。COFFEE HOLDING CO INC同比增速更快（30.8% vs -36.9%）。COFFEE HOLDING CO INC自由现金流更多（$265.4K vs $-6.6M）。过去两年COFFEE HOLDING CO INC的营收复合增速更高（19.2% vs -34.4%）
黑步枪咖啡公司是一家总部位于美国犹他州盐湖城的咖啡企业，由前美国陆军绿色贝雷帽成员埃文·黑弗于2014年创立。2017年，该公司因回应星巴克招聘一万名难民的承诺，宣布将招聘一万名退伍军人而受到全美国关注。
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
JVA vs MED — 直观对比
营收规模更大
MED
是对方的2.7倍
$27.7M
营收增速更快
JVA
高出67.7%
-36.9%
自由现金流更多
JVA
多$6.9M
$-6.6M
两年增速更快
JVA
近两年复合增速
-34.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $27.7M | $75.1M |
| 净利润 | $811.5K | — |
| 毛利率 | 8.5% | 69.4% |
| 营业利润率 | 2.8% | -10.4% |
| 净利率 | 2.9% | — |
| 营收同比 | 30.8% | -36.9% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.15 | $-1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JVAMED
| Q4 25 | $27.7M | $75.1M | ||
| Q3 25 | $23.9M | $89.4M | ||
| Q2 25 | $23.3M | $105.6M | ||
| Q1 25 | $21.3M | $115.7M | ||
| Q4 24 | $21.2M | $119.0M | ||
| Q3 24 | $18.8M | $140.2M | ||
| Q2 24 | $19.0M | $168.6M | ||
| Q1 24 | $19.5M | $174.7M |
净利润JVAMED
| Q4 25 | $811.5K | — | ||
| Q3 25 | $-1.2M | $-2.3M | ||
| Q2 25 | $644.1K | $2.5M | ||
| Q1 25 | $1.2M | $-772.0K | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $626.8K | $1.1M | ||
| Q2 24 | $-21.8K | $-8.2M | ||
| Q1 24 | $351.0K | $8.3M |
毛利率JVAMED
| Q4 25 | 8.5% | 69.4% | ||
| Q3 25 | 12.2% | 69.5% | ||
| Q2 25 | 18.9% | 72.6% | ||
| Q1 25 | 26.9% | 72.8% | ||
| Q4 24 | 23.2% | 74.1% | ||
| Q3 24 | 20.9% | 75.4% | ||
| Q2 24 | 19.5% | 73.2% | ||
| Q1 24 | 17.8% | 72.8% |
营业利润率JVAMED
| Q4 25 | 2.8% | -10.4% | ||
| Q3 25 | -4.6% | -4.6% | ||
| Q2 25 | 3.8% | -1.0% | ||
| Q1 25 | 7.5% | -1.1% | ||
| Q4 24 | 8.0% | 0.6% | ||
| Q3 24 | 3.8% | 1.5% | ||
| Q2 24 | -0.4% | -4.7% | ||
| Q1 24 | 3.2% | 4.5% |
净利率JVAMED
| Q4 25 | 2.9% | — | ||
| Q3 25 | -5.0% | -2.5% | ||
| Q2 25 | 2.8% | 2.3% | ||
| Q1 25 | 5.4% | -0.7% | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 3.3% | 0.8% | ||
| Q2 24 | -0.1% | -4.8% | ||
| Q1 24 | 1.8% | 4.8% |
每股收益（稀释后）JVAMED
| Q4 25 | $0.15 | $-1.64 | ||
| Q3 25 | $-0.21 | $-0.21 | ||
| Q2 25 | $0.11 | $0.22 | ||
| Q1 25 | $0.20 | $-0.07 | ||
| Q4 24 | $0.22 | $0.08 | ||
| Q3 24 | $0.11 | $0.10 | ||
| Q2 24 | $0.00 | $-0.75 | ||
| Q1 24 | $0.06 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $701.9K | $167.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $27.6M | $198.9M |
| 总资产 | $42.0M | $248.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JVAMED
| Q4 25 | $701.9K | $167.3M | ||
| Q3 25 | $979.8K | $173.5M | ||
| Q2 25 | $1.8M | $162.7M | ||
| Q1 25 | $2.4M | $164.6M | ||
| Q4 24 | $1.4M | $162.3M | ||
| Q3 24 | $3.1M | $170.0M | ||
| Q2 24 | $2.4M | $163.5M | ||
| Q1 24 | $2.4M | $156.4M |
股东权益JVAMED
| Q4 25 | $27.6M | $198.9M | ||
| Q3 25 | $26.8M | $214.7M | ||
| Q2 25 | $28.0M | $216.0M | ||
| Q1 25 | $27.3M | $211.0M | ||
| Q4 24 | $26.2M | $210.1M | ||
| Q3 24 | $24.9M | $207.3M | ||
| Q2 24 | $24.3M | $205.3M | ||
| Q1 24 | $24.3M | $211.0M |
总资产JVAMED
| Q4 25 | $42.0M | $248.0M | ||
| Q3 25 | $45.9M | $268.2M | ||
| Q2 25 | $39.7M | $269.3M | ||
| Q1 25 | $38.9M | $280.0M | ||
| Q4 24 | $34.0M | $284.2M | ||
| Q3 24 | $33.1M | $291.2M | ||
| Q2 24 | $34.9M | $293.5M | ||
| Q1 24 | $37.6M | $302.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $377.7K | $-5.3M |
| 自由现金流经营现金流 - 资本支出 | $265.4K | $-6.6M |
| 自由现金流率自由现金流/营收 | 1.0% | -8.8% |
| 资本支出强度资本支出/营收 | 0.4% | 1.8% |
| 现金转化率经营现金流/净利润 | 0.47× | — |
| 过去12个月自由现金流最近4个季度 | $-5.2M | $1.2M |
8季度趋势，按日历期对齐
经营现金流JVAMED
| Q4 25 | $377.7K | $-5.3M | ||
| Q3 25 | $-3.8M | $12.1M | ||
| Q2 25 | $-1.2M | $-3.4M | ||
| Q1 25 | $-401.9K | $3.4M | ||
| Q4 24 | $222.0K | $-4.9M | ||
| Q3 24 | $1.8M | $9.1M | ||
| Q2 24 | $-1.2M | $13.1M | ||
| Q1 24 | $4.6M | $7.3M |
自由现金流JVAMED
| Q4 25 | $265.4K | $-6.6M | ||
| Q3 25 | $-3.9M | $10.8M | ||
| Q2 25 | $-1.2M | $-4.8M | ||
| Q1 25 | $-419.8K | $1.9M | ||
| Q4 24 | — | $-7.2M | ||
| Q3 24 | $1.8M | $7.7M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | — | $5.4M |
自由现金流率JVAMED
| Q4 25 | 1.0% | -8.8% | ||
| Q3 25 | -16.3% | 12.0% | ||
| Q2 25 | -5.0% | -4.5% | ||
| Q1 25 | -2.0% | 1.6% | ||
| Q4 24 | — | -6.1% | ||
| Q3 24 | 9.4% | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 3.1% |
资本支出强度JVAMED
| Q4 25 | 0.4% | 1.8% | ||
| Q3 25 | 0.2% | 1.5% | ||
| Q2 25 | 0.1% | 1.3% | ||
| Q1 25 | 0.1% | 1.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | 0.2% | 1.0% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.1% |
现金转化率JVAMED
| Q4 25 | 0.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.79× | -1.36× | ||
| Q1 25 | -0.35× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 2.90× | 8.04× | ||
| Q2 24 | — | — | ||
| Q1 24 | 13.09× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
